A UNC Chapel Hill Ph.D. graduate who is the founder and CEO of Koya Medical, a team dedicated to transforming chronic lymphatic and venous disease. Andy also serves as Chairman and board director with an eye-care and urology health venture. Previously, he led Oculeve, a first-in-class healthcare venture funded by NEA, KPCB, and Versant to treat ocular disorders with a revolutionary neuromodulation platform. Oculeve was acquired by Allergan Plc.
Brian Miller, M.D., M.B.A., M.P.H. is an Assistant Professor of Medicine and Business (courtesy) at the Johns Hopkins University, where he is a practicing hospitalist, health policy researcher, and health policy analyst. He is a consultant to the FTC Bureau of Consumer Protection on health insurance and is a member of the Medicare Evidence Development & Coverage Advisory Committee.
Peter C. Johnson, M.D., is the president and CEO of Scintellix, LLC, a biomedical technology consulting company in Raleigh, NC and the VP, R&D and Medical and Scientific Affairs, Vancive Medical Technologies – an Avery Dennison business.
George Ligler is a private consultant in Fuquay Varina, North Carolina. He has extensive experience in information management and software and computer system engineering.
Mr. Rosen serves on the board of directors of AcelRx, Inc., Alcobra, Ltd. (Chairman since 2014), Entrega, Inc., and Kala Pharmaceuticals, Inc. He has been serving as interim CEO of AcelRx since April 1, 2015. From 2004 to 2008, he was Vice President, Commercial Strategy at Gilead Sciences, Inc.
Sheila Mikhail co-founded and was the initial CEO of AskBio from 2002 through 2007. Ms. Mikhail left the company to become CEO of NanoCor Therapeutics, Inc., an AskBio SPE. Most recently, Ms. Mikhail co-founded and was CEO of Bamboo Therapeutics, Inc., which in 20 months raised $50 million, advanced a therapeutic for GAN into the clinic, completed Pre-IND studies for the Duchenne Muscular Dystrophy therapeutic, and built a GMP manufacturing facility.
Dr. Janie Fouke has long been active in the field of biomedical engineering.From 1981 to 1999, Dr. Fouke rose through the faculty ranks at Case Western Reserve University with teaching and research interests in medical instrument design and development. Her work has been critical to the understanding of the etiology of airway diseases such as asthma and the pulmonary effects of environmental pollutants.
Dr. Shaffer has served as a director of our company since January 2012. Since 2011, Dr. Shaffer has served as a Venture Partner with Hatteras Venture Partners, an investment firm, and as Managing Director of Hatteras Discovery, which invests in early-stage companies in the life sciences industry sector. From 1995 to March 2010, Dr. Shaffer served in increasing leadership positions at Inspire Pharmaceuticals, a publicly held biopharmaceutical company, beginning as the company’s first full-time employee and Director of Clinical Operations and eventually being appointed as Chief Executive Officer and a director of the company in 1999, as its President in 2005 and a member of its Development Committee in 2009.
John Ryals, Ph.D. is President and Chief Executive Officer of Metabolon, a biotechnology firm headquartered in RTP that focuses on a systems biology approach to understanding the metabolic signatures of biological and clinical samples and serves the biotech and pharma industries. Prior to founding Metabolon, Ryals was chief executive officer, president and founder of Paradigm Genetics, Inc., a publicly traded agricultural biotechnology company focused on industrializing the process of gene function discovery. Dr. Ryals has 30 years of experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He currently serves on the board of directors at AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a B.A. in biology and chemistry from the University of North Texas and M.S. and Ph.D. degrees in molecular biology from the University of Texas at Dallas.
William N. Starling is Managing Director of Synergy Life Science Partners, LP, a $143 million Venture Capital Partnership and Chief Executive Officer of Synecor, LLC, (Synecor) a business generator of new Life Science companies based in Research Triangle Park (RTP), North Carolina.
